Clinuvel completes pre-clinical program for SCENESSE
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- SCENESSE successful in Phase IIa vitiligo study
- Placement
- Observations from Clinuvels US vitiligo study published
- Five month study follow up - SCENESSE in vitiligo (CUV102)
- Clinuvel clears EMA manufacturing audit
Later from Clinuvel Pharmaceuticals
- Clinuvel books European Pre-Submission Meeting for SCENESSE
- Clinuvel completes first Phase II US study
- Clinuvel granted Australian formulation patent
- Clinuvel presents SCENESSE to global porphyria conference
- Clinuvel records first A$1 million in sales
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals